Wall Street giant Goldman Sachs has emerged as the lead market maker of the $34 million Capital Group US Large Growth ETF.

The company, mired in too many scandals and setbacks to print, lost nearly $12 billion when all was said and done in 2024.

Staffing shortages, rising prescription drug use, and costly new therapies have driven inflation in the medical sector.

The faith-based ETF segment focuses less on generating alpha and more on adhering to religious principles and values.

On Monday, Tesla and Samsung announced a $16.5 billion multiyear deal for the latter to provide all-important artificial ...

The growing expectation that clients should be able to get in touch with their advisors at a moment’s notice can disrupt ...

Many advisors see AI as a big influencer in their jobs in the future, and one researcher expects the technology to be acting ...

Experts said the GENIUS Act, signed into law this month, will make advisors more confident about getting into digital ...

The world’s leading beverage company plans to add a cane-sugar version of its namesake beverage in the US. There was some ...

In its fiscal year 2025 earnings call, the company said it projects new tariffs will saddle it with $1 billion in additional costs this year.

The White House’s stated goal was to smooth the path of progress. Its AI Action Plan, a sweeping strategy document unveiled ...

While many companies maintain on-premise networks and servers, believing that they are more secure than the cloud, ...